These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15879693)

  • 1. Childhood and adolescent diabetes.
    Dunger DB; Regan FM; Acerini CL
    Endocr Dev; 2005; 9():107-120. PubMed ID: 15879693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
    Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-I and diabetes in adolescence.
    Dunger DB; Acerini CL
    Diabetes Metab; 1998 Apr; 24(2):101-7. PubMed ID: 9592633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.
    Mohamed-Ali V; Pinkney J
    Treat Endocrinol; 2002; 1(6):399-410. PubMed ID: 15832492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mecasermin (recombinant human insulin-like growth factor I).
    Rosenbloom AL
    Adv Ther; 2009 Jan; 26(1):40-54. PubMed ID: 19198769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR; Moses AC; McKay MJ; Sommer A; Rosen DM; Ruckle J
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant IGF-I therapy in insulin-dependent diabetes mellitus.
    Savage MO; Dunger DB
    Diabetes Metab; 1996 Jul; 22(4):257-60. PubMed ID: 8767172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus.
    Dunger DB; Cheetham TD; Crowne EC
    Metabolism; 1995 Oct; 44(10 Suppl 4):119-23. PubMed ID: 7476304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.
    Klevebro S; Hellgren G; Hansen-Pupp I; Wackernagel D; Hallberg B; Borg J; Pivodic A; Smith L; Ley D; Hellström A
    Growth Horm IGF Res; 2020 Feb; 50():1-8. PubMed ID: 31756675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus.
    Cheetham TD; Holly JM; Baxter RC; Meadows K; Jones J; Taylor AM; Dunger DB
    J Endocrinol; 1998 Apr; 157(1):81-7. PubMed ID: 9614361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus.
    Dunger DB; Cheetham TD
    Horm Res; 1996 Jul; 46(1):2-6. PubMed ID: 8854134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
    Regan FM; Williams RM; McDonald A; Umpleby AM; Acerini CL; O'Rahilly S; Hovorka R; Semple RK; Dunger DB
    J Clin Endocrinol Metab; 2010 May; 95(5):2113-22. PubMed ID: 20233784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.